ENTG 10-Q filed 2026-10-29 | Key takeaways
ENTG filed its 10-Q; the most relevant disclosure change is expanded Long-term debt and credit facilities: Term Loans B were fully repaid as of September 26, 2026 ($450.0 million at December 31, 2025 reduced to $0). The Revolving Credit Facility was amended on April 29, 2026 to increase commitments from $575.0 million to $750.0 million and extend maturity to April.
Key takeaways
Revenue: Q3 net sales $1,005.7 million (up 24.6% y/y from $807.1 million); nine-month sales $2,700.8 million (up 13.8% y/y)
Debt: Term Loans B fully repaid ($450 million at December 31, 2025 reduced to $0); total debt $3,295.0 million at September 26, 2026
Depreciation: January 2026 useful life extension reduced Q3 depreciation by $17.9 million and nine-month depreciation by $55.6 million
Subsequent event: Q4 2026 dividend of $0.10 per share declared October 14, 2026, payable November 18, 2026
Segments: APS Q3 sales $604.9 million (up 31% y/y), segment profit $212.7 million (up 80% y/y); MS Q3 sales $404.1 million (up 16% y/y), segment profit $84.3 million (up 29% y/y)
Tariff refunds: $8.3 million IEEPA tariff refunds recognized in Q3 2026 cost of sales
Key metrics
Disclosure changes
- Long-term debt and credit facilities
Term Loans B were fully repaid as of September 26, 2026 ($450.0 million at December 31, 2025 reduced to $0). The Revolving Credit Facility was amended on April 29, 2026 to increase commitments from $575.0 million to $750.0 million and extend maturity to April 29, 2031 from July 6, 2027.
Full repayment of Term Loans B eliminates $450 million in debt and reduces future interest expense. Expanded revolving facility provides additional liquidity. - Property, plant and equipment - change in useful lives
In January 2026, the company extended estimated useful lives of PP&E: buildings and improvements increased from 5-35 years to 12-40 years; manufacturing equipment increased from 5-10 years to 14 years; canisters and cylinders increased from 3-12 years to 3-19 years; molds increased from 3-5 years to 9 years; lab equipment increased from 3-8 years to 9 years. Q3 2026 depreciation expense reduced by $17.9 million, increasing net income by approximately $14.8 million.
This accounting change reduced depreciation expense, positively impacting Q3 and YTD net income and margins; full-year 2026 depreciation expected to be reduced by approximately $73.0 million. - Restructuring costs
Q3 2026 restructuring charges of $1.5 million (employee termination benefits); YTD restructuring charges of $11.2 million ($7.4 million employee termination, $3.8 million asset impairment), including actions associated with planned wind-down of Life Sciences Fluid Management business and manufacturing facility closure.
Life Sciences Fluid Management wind-down represents a new discrete restructuring initiative not present in prior year; YTD charges decreased vs prior year. - Other expense, net
YTD 2026 other expense of $9.4 million included equity investment impairment of $6.7 million (reducing carrying basis to zero) and loss on debt extinguishment of $3.9 million.
Equity investment impairment is a new item in 2026 not present in prior year; partially offset by lower foreign currency losses. - Subsequent events - dividend
October 14, 2026: Board declared Q4 2026 quarterly cash dividend of $0.10 per share payable November 18, 2026 to shareholders of record October 28, 2026.
Dividend policy maintained at $0.10 per share per quarter. - Tariff refunds
Q3 2026 included $8.3 million of refunds of IEEPA tariffs recognized in cost of goods sold; these tariffs were paid from April 2025 through February 2026.
Discrete recovery of previously paid tariffs positively impacted Q3 2026 gross margin by approximately 82 basis points.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow ENTG in real time
Get material earnings, filing, IR, and earnings-call alerts by email.